The biological analyses and antiproliferative activity of the synthesized compounds (3a–p) as potential candidates for prostate cancer therapy (Figure 2) showed excellent anticancer properties against the tested AR+LNCaP and AR-PC-3 prostate cancer cell lines. The gene discussed is AR; the disease is prostate carcinoma.